Low‐dose short‐term hepatitis B immunoglobulin with high genetic barrier antivirals: the ideal post‐transplant hepatitis B virus prophylaxis?

Abstract

In a large cohort of LDLT recipients for HBV-related liver disease, use of low-dose short-term HBIG with high genetic barrier drugs results in a substantially lower incidence of HBV recurrence, even in high-risk patients.